Doctors should be alert for symptoms of erythrodermic psoriasis or exfoliative dermatitis in their patients taking ustekinumab, the TGA advises. To 20 May 2015, the safety body has received one report of erythrodermic psoriasis associated with ustekinumab treatment, and no reports that specified exfoliative dermatitis as an adverse event. However, although there was insufficient information to ...
Ustekinumab linked with serious skin condition
4 Oct 2015